Barclays Maintains Overweight on Travere Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Travere Therapeutics (NASDAQ:TVTX) but lowers the price target from $31 to $12.
September 22, 2023 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has lowered its price target for Travere Therapeutics from $31 to $12, while maintaining an Overweight rating.
The lowering of the price target by Barclays indicates a potential decrease in the short-term value of Travere Therapeutics' stock. However, the maintained Overweight rating suggests that Barclays still sees potential in the company's long-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100